Autologous aPD-L1 armored anti-CD22 CAR T cells - Hebei Senlang Biotechnology
Alternative Names: SL22P CAR-T cellsLatest Information Update: 28 Sep 2023
At a glance
- Originator Hebei Senlang Biotechnology
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunoglobulin Fv fragments; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in China (Parenteral, Infusion)
- 01 Aug 2020 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater) in China (unspecified route)